Eli Lilly is now offering four doses of Zepbound in self-administration vials. The lower-cost self-pay option targets people on Medicare and those who can no longer access compounded tirzepatide.

India's largest drugmaker by revenue Sun Pharmaceutical is aiming to launch its experimental anti-obesity and type 2 diabetes ...

Altimmune's pemvidutide shows promise in treating MASH and obesity, with upcoming Phase 2b results poised to shape its market ...

Eli Lilly is seeking to further cement its stance as a leader in weight loss drugs in an ad campaign calling out “unapproved” medications.

Once again, Eli Lilly is using Hollywood’s biggest night as a platform to speak out on a hot-button issue in pharma. | Once ...

Eli Lilly launched an ad campaign on Friday, cautioning patients against the risks of unapproved weight-loss drugs in its ...

“The thing most amazing about them is how these drugs suddenly alter the dopamine-related reward pathway in the brain making us less of a slave to cravings. Today, 73% of Americans are obese or ...

Hugely popular weight loss drugs known as GLP-1's are finally getting cheaper, well at least one is, and that's the case with ...

Zepbound may not be as widely known as its competitors, but the weight-loss drug may soon be more accessible than the rest.

Eli Lilly is expanding the supply and cutting the costs of its weight-loss drug Zepbound, broadening access to more patients ...

In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...

Discover Eli Lilly's latest offering of discounted high-dose Zepbound vials, now available for $499 for a four-week supply.